News for Healthier Living

Yamo Pharmaceuticals Announces Autism Trial Registry Following Global Surge in Family Interest

Yamo Pharmaceuticals LLC ("Yamo"), the developer of L1-79, an investigational drug for the core symptoms of autism spectrum disorder ("ASD"), today announced it has received more than 6,000 inquiries from families in more than 90 countries, including over 2,000 since national coverage in The Washington Times and the New York Post on October 1. Families can register for updates on Yamo's planned Phase 3 program at access.yamopharma.com.

October 9, 2026


October 10 2026

October 9 2026

October 8 2026

October 7 2026

October 6 2026

October 5 2026

October 2 2026

October 1 2026

September 30 2026

September 29 2026

September 28 2026

September 27 2026